COMPANY

Electra Therapeutics

HQ: South San Francisco, CA source · electra-therapeutics.com ↗ · West Coast

Keywords: antibody T Cell Malignancies Secondary Hemophagocytic Lymphohistiocytosis ELA026

Location: South San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series C · $183M · announced Oct 22, 2025 Company release ↗
Source quote
- Oct 22, 2025 · Company release ↗
  “Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer Proceeds will fund a global pivotal trial of lead product candidate”

Raises announced in these releases: $183M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Sep 18, 2026 Raise IPO: $350M (total, as published), announced Sep 18, 2026. Source: company release on GlobeNewswire. source ↗
Feb 17, 2026 Trial start Phase 1: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) source ↗
Oct 22, 2025 Raise Private equity round — Series C: $183M (total, as published), announced Oct 22, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 30, 2025 SEC Form D ↗
Oct 22, 2025 Raise Series C · $183M source ↗
May 19, 2022 Trial start Phase 2/Phase 3: Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) source ↗
Oct 18, 2021 Trial start Phase 1: Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers source ↗

2027-06 (ESTIMATED) · Phase 2/Phase 3 · Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) · NCT05416307
2028-06 (ESTIMATED) · Phase 1 · A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) · NCT07465835

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $533.0M. Last 2 years.

Sep 18, 2026 IPO: $350M (total, as published), announced Sep 18, 2026. Source: company release on GlobeNewswire. source ↗
Oct 22, 2025 Private equity round — Series C: $183M (total, as published), announced Oct 22, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 30, 2025 SEC Form D ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07465835	A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)	Phase 1	Recruiting	Feb 17, 2026	2028-06 (estimated)
NCT05416307	Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)	Phase 2/Phase 3	Recruiting	May 19, 2022	2027-06 (estimated)
NCT05556863	Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers	Phase 1	Completed	Oct 18, 2021	Nov 20, 2023 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2025-10-30 Raise Private raise (SEC Form D): $134.2M sold of $184.1M offered; issuer “Electra Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗